Monte Rosa Therapeutics (GLUE) Cash & Equivalents (2023 - 2025)
Historic Cash & Equivalents for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $401.6 million.
- Monte Rosa Therapeutics' Cash & Equivalents rose 21983.04% to $401.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.6 million, marking a year-over-year increase of 21983.04%. This contributed to the annual value of $381.0 million for FY2024, which is 6113.91% up from last year.
- Per Monte Rosa Therapeutics' latest filing, its Cash & Equivalents stood at $401.6 million for Q3 2025, which was up 21983.04% from $300.9 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Cash & Equivalents high stood at $401.6 million for Q3 2025, and its period low was $47.0 million during Q2 2023.
- Its 3-year average for Cash & Equivalents is $195.2 million, with a median of $125.6 million in 2024.
- In the last 5 years, Monte Rosa Therapeutics' Cash & Equivalents surged by 6113.91% in 2024 and then soared by 23591.41% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Cash & Equivalents stood at $236.4 million in 2023, then surged by 61.14% to $381.0 million in 2024, then rose by 5.42% to $401.6 million in 2025.
- Its Cash & Equivalents stands at $401.6 million for Q3 2025, versus $300.9 million for Q2 2025 and $335.1 million for Q1 2025.